Objective-Therapeutic interventions that increase plasma levels of high-density lipoproteins and apolipoprotein A-I (apoA-I) A-I, the major high-density lipoprotein apolipoprotein, improve glycemic control in people with type 2 diabetes mellitus. High-density lipoproteins and apoA-I also enhance insulin synthesis and secretion in isolated pancreatic islets and clonal β-cell lines. This study identifies the signaling pathways that mediate these effects. Approach and Results-Incubation with apoA-I increased cAMP accumulation in Ins-1E cells in a concentration-dependent manner. The increase in cAMP levels was inhibited by preincubating the cells with the cell-permeable, transmembrane adenylate cyclase inhibitor, 2′5′ dideoxyadenosine, but not with KH7, which inhibits soluble adenylyl cyclases. Incubation of Ins-1E cells with apoA-I resulted in colocalization of ATP-binding cassette transporter A1 with the Gαs subunit of a heterotrimeric G-protein and a Gαs subunit-dependent increase in insulin secretion. Incubation of Ins-1E cells with apoA-I also increased protein kinase A phosphorylation and reduced the nuclear localization of forkhead box protein O1 (FoxO1). Preincubation of Ins-1E cells with the protein kinase A-specific inhibitors, H89 and PKI amide, prevented apoA-I from increasing insulin secretion and mediating the nuclear exclusion of FoxO1. Transfection of Ins-1E cells with a mutated FoxO1 that is restricted to the nucleus confirmed the requirement for FoxO1 nuclear exclusion by blocking insulin secretion in apoA-I-treated Ins-1E cells. ApoA-I also increased Irs1, Irs2, Ins1, Ins2, and Pdx1 mRNA levels.
R ecent evidence suggests that high-density lipoproteins (HDL) play an important role in glucose metabolism and that they may protect against the development of type 2 diabetes mellitus. 1 People with type 2 diabetes mellitus typically have lower HDL cholesterol levels than healthy subjects. 2, 3 Low plasma HDL cholesterol levels are also predictive of progression to type 2 diabetes mellitus in people with pre-diabetes mellitus. 4 Increasing HDL levels with reconstituted HDL infusions consisting of apolipoprotein A-I (apoA-I), the main HDL apolipoprotein, complexed with phosphatidylcholine in people with type 2 diabetes mellitus reduces blood glucose levels, increases plasma insulin levels, and improves pancreatic β-cell function. 5 Treatment with the cholesteryl ester transfer protein inhibitor, torcetrapib, which increases plasma HDL cholesterol levels by ≈70%, also improves glycemic control in people with type 2 diabetes mellitus. 6 ApoA-I seems to be responsible for conferring antidiabetic properties to HDL. Thus, apoA-I-deficient mice have impaired glucose tolerance, decreased skeletal muscle and hepatic AMP-activated protein kinase (AMPK) phosphorylation, as well as increased hepatic glucose production. 7 Mice that overexpress human apoA-I, by contrast, have improved insulin sensitivity and do not become obese when fed a high-fat diet. 8 A single infusion of apoA-I also improves glucose tolerance and increases insulin secretion in insulin-resistant mice. 9 We have previously reported that treatment of isolated islets and the MIN6 clonal β-cell line with either apoA-I or reconstituted HDL increases insulin secretion and insulin gene transcription under both basal and glucose-stimulated conditions. 10 These effects were dependent, at least in part, on the ATP-binding cassette transporters, ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1), and scavenger receptor class B type 1 (SR-B1). 10 However, the mechanisms underlying these effects remain uncharacterized. Given the current interest in apoA-Iand HDL-raising therapeutics, and their potential to improve glycemic control in people with type 2 diabetes mellitus, 6 determining the mechanism by which apoA-I increases insulin synthesis and secretion without having deleterious effects on β-cell function is clearly of importance.
Previous reports in different cell types have provided clues about signaling pathways that may explain the antidiabetic properties of apoA-I. For example, the interaction of apoA-I with ABCA1 activates cAMP in cultured human fibroblasts and Chinese hamster ovary cells. 11 ApoA-I also activates protein kinase A (PKA) and increases ABCA1 phosphorylation and expression in RAW macrophages and fibroblasts. 11, 12 Other studies have established that apoA-I activates janus kinase 2 in baby hamster kidney cells, 13 AMPK in C2C12 myocytes, 7 and protein kinase C 14 and cell division control protein 42 signaling in human fibroblasts. 15 We, and others, have further reported that apoA-I regulates intracellular Ca2+ levels in MIN6 cells, baby hamster kidney cells, and RAW macrophages. 10, 16 The present study establishes that apoA-I increases insulin secretion in the Ins-1E clonal β-cell line and isolated primary islets via a heterotrimeric G-protein-cAMP-PKA signaling pathway. The results also show that the apoA-I-mediated increase in insulin synthesis in Ins-1E cells involves nuclear exclusion of forkhead box protein O1 (FoxO1) and increased transcription of insulin response genes and genes involved in β-cell function and survival.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

ApoA-I Increases Insulin Secretion From Ins-1E Cells in an ABCA1-and SR-BI-Dependent Manner
We have previously reported that apoA-I increases insulin secretion from MIN6 cells. 10 To confirm that this is also the case for Ins-1E cells, incubations were performed with increasing concentrations of apoA-I ( Figure I in the online-only Data Supplement). After 1 hour of incubation with apoA-I (final concentration, 0.125 mg/mL), the insulin concentration in the medium increased from 46.5±5.6 to 89.1±10.1 ng insulin/mg protein (P<0.001). Incubation for 1 hour in the presence of apoA-I at a final concentration of 1 mg/mL further increased the insulin concentration in the medium to 164.4±9.0 ng insulin/mg protein (P<0.001).
We have also reported that apoA-I increases insulin secretion from MIN6 cells in an ABCA1-and SR-BI-dependent manner. 10 To confirm this in Ins-1E cells, transfections were performed with scrambled small interfering RNA (siRNA), ABCA1 siRNA, SR-BI siRNA, and ABCG1 siRNA, which decreased ABCA1, SR-B1, and ABCG1 protein expression by 56.8±4.6%, 74.0±7.94%, and 70.1±5.2%, respectively ( Figure IIA and IIB in the online-only Data Supplement). Transfection of Ins-1E cells with scrambled siRNA or ABCG1 siRNA had no effect on apoA-I-mediated insulin secretion. When, by contrast, ABCA1 and SR-BI were knocked down, insulin secretion decreased from 165.0±25.4 to 59.5±13.7 and 52.0±15.4 ng insulin/mg protein, respectively (P<0.005 for both versus scrambled siRNA-transfected cells; Figure IIC in the online-only Data Supplement).
As reported previously, 10 incubation of Ins-1E cells with apoA-I under basal and high glucose conditions did not alter cellular cholesterol levels ( Table II in the online-only Data Supplement). Although this suggests that apoA-I increases insulin secretion from Ins-1E cells by a mechanism that is independent of cellular cholesterol depletion, the possibility that the insulin secretion was increased because of alterations in the subcellular localization of cholesterol cannot be excluded.
ApoA-I Increases Insulin Secretion From Ins-1E Cells Independent of the Akt/Protein Kinase B, Janus Kinase 2, Protein Kinase C, and AMPK Signaling Pathways
Because the Akt/protein kinase B (PKB) signaling pathway plays a key role in β-cell function and insulin secretion, 17 and this pathway is activated by HDL in endothelial cells, 18 we next asked whether this could explain the increased insulin secretion in apoA-I-treated Ins-1E cells. Figure 
ApoA-I Increases cAMP Accumulation in Ins-1E Cells in a Transmembrane Adenylyl Cyclase-Dependent Manner
Because apoA-I increases cAMP levels in fibroblasts and Chinese hamster ovary cells, 11 cAMP levels were also quantified in Ins-1E cells. These experiments were conducted under low-glucose conditions to minimize glucose-mediated cAMP induction. 19 Incubation with apoA-I increased Ins-1E cAMP levels in a concentration-dependent manner ( Figure 1A) . At final apoA-I concentrations of 0.5 and 1.0 mg/mL, Ins-1E cAMP levels increased from 20.1±4.8 to 57.6±5.9 pmol/mg cell protein (P<0.01) and 95.5±12.1 pmol/mg cell protein (P<0.001), respectively.
To determine whether the increase in cAMP levels involved transmembrane or soluble adenylyl cyclases, Ins-1E cells were preincubated with 2′5′ dideoxyadenosine or KH7, which respectively inhibit transmembrane and soluble adenylyl cyclases, before addition of apoA-I ( Figure 1B) . Incubation with apoA-I increased Ins-1E cAMP levels from 45.3±4.7 to 119.2±42.6 pmol/mg cell protein in the control cells, (P<0.05). When the cells were treated with KH7 before incubation with 
ApoA-I Increases Colocalization of ABCA1 With the Heterotrimeric G-Protein Gα s Subunit
Because the Gα s subunit of heterotrimeric G-proteins can activate adenylyl cyclases, we next asked whether this is the link between the interaction of apoA-I with ABCA1 and transmembrane adenylyl cyclase activation. Transfection of Ins-1E cells with heterotrimeric G-protein Gα s subunit siRNA reduced Gα s protein levels by 62.2±9.7% relative to control (Figure 2A and 2B). Incubation with apoA-I increased insulin secretion in the scrambled siRNA-transfected and -nontransfected cells to the same extent ( Figure 2C ). When cells in which the Gα s subunit was knocked down were incubated with apoA-I, insulin secretion decreased from 189.6±25.2 ng/mg protein (control) to 98.35±25.96 ng/mg protein (P<0.001 versus scrambled siRNA-transfected cells; Figure 2C ). Incubation with apoA-I also increased the colocalization of ABCA1 and the Gα s subunit ( Figure 2D ), with the Pearson coefficient increasing from 0.04±0.03 to 0.17±0.05 in Ins-1E cells incubated with PBS (P<0.001 versus negative control) and to 0.3±0.04 in cells incubated with apoA-I (P<0.001 versus PBS; Figure 2E ). The specificity of the anti-ABCA1 antibody was confirmed by establishing that colocalization of ABCA1 and the Gα s subunit was minimal when ABCA1 was knocked down in Ins-1E cells ( Figure IV in the online-only Data Supplement).
ApoA-I Increases Insulin Secretion From Ins-1E Cells and Primary Islets in a PKA-Dependent Manner
To determine if PKA was activated by the increase in cAMP levels, Ins-1E cells were incubated with apoA-I under basal conditions. This increased PKA phosphorylation by 103.9±19.6% at 15 minutes ( Figure 3A and 3B; P<0.001 versus control) and by 54.2±19.6% (P<0.001 versus control) at 30 minutes. PKA phosphorylation levels had returned to baseline by 60 minutes. Incubation of primary mouse islets with apoA-I for 15 minutes increased PKA phosphorylation by 76.4±15.1% (P<0.01; Figure 3C and 3D).
Incubations were also performed with the PKA-specific inhibitors, H89 and PKI amide. Incubation of Ins-1E cells with Figure 3F ) and primary islets ( Figure 3G ) with H89 and PKI amide under high glucose conditions also abolished the apoA-I-mediated increase in insulin secretion ( Figure 3F ).
ApoA-I Mediates Nuclear Translocation of FoxO1 in a PKA-Dependent Manner
As reported previously, 94.9±8.4% of the total cellular FoxO1 was localized in the nucleus of Ins-1E cells after 6 hours of serum starvation (Figure 4A, top) . 20 The intracellular distribution of FoxO1 was not affected by incubation with H89 for 30 minutes. When, by contrast, the cells were incubated with apoA-I, only 14.3±18.8% of the FoxO1 remained in the nucleus (P<0.001 versus control). Preincubation of the cells with H89 before incubation with apoA-I increased the nuclear localization of FoxO1 to 86.8±12.7% (P<0.001 versus incubation with apoA-I alone).
Ability of ApoA-I to Increase Long-Term Insulin Secretion From Ins-1E Cells Is Dependent on Nuclear Exclusion of FoxO1
To determine whether the ability of apoA-I to increase longterm insulin production depends on continued nuclear exclusion of FoxO1, Ins-1E cells were transiently transfected with pCMV5 vectors encoding for wild-type FoxO1, FoxO1-ADA (a transcriptionally active FoxO1 mutant that resides exclusively in the nucleus), or an empty pCMV5 vector. FoxO1 protein expression was comparable in the FoxO1 and FoxO1-ADA transfected cells ( Figure 5A and 5B) . Incubation of the transfected cells with PBS had no effect on insulin secretion ( Figure 5C , white bars). Incubation with apoA-I increased the insulin concentration in the medium from 287.8±62.4 and 259.6±59.0 to 836.2±34.5 and 789.0±98.5 ng insulin/mg cell protein in the cells transfected with empty vector and the vector encoding for FoxO1, respectively (P<0.001 versus PBS for both; Figure 5C , black bars). Insulin secretion was reduced to 401.02±55.69 ng insulin/mg cell protein when the FoxO1-ADA-transfected cells were incubated with apoA-I (P<0.001).
ApoA-I Increases Expression of FoxO1 Target Genes and β-Cell Survival Genes
As reported previously, 10 Ins1 and Ins2 mRNA levels increased 2.1-fold (P<0.001), and 2.8-fold (P<0.005), respectively, when Ins-1E cells were incubated for 16 hours with apoA-I. Insulin receptor substrate 1 (IRS1) and IRS2 mRNA levels increased 4.7-fold (P<0.01) and 2.9-fold, respectively (P<0.05) ( Figure 6 ). Nuclear exclusion of FoxO1 by apoA-I also increased transcription of the β-cell survival factor Pdx1 5.3-fold (P<0.001). 21
Discussion
Emerging evidence suggests that increasing plasma HDL cholesterol and apoA-I levels improves glycaemic control in people with type 2 diabetes mellitus. 5, 6 The present study indicates that this may relate to the ability of HDL and apoA-I to increase insulin secretion and production in pancreatic β-cells 9,10,22 and the activation of a G-protein-cAMP-PKA-FoxO1 signaling pathway. The results also establish that apoA-I increases transcription of insulin production genes and expression of the β-cell survival gene, Pdx1.
Insulin secretion is impaired in pancreatic β-cells with elevated cholesterol levels, 23 and this detrimental effect can be rectified by removing cholesterol from the cells with agents such as cyclodextrin that act as cholesterol scavengers. Because apoA-I is the main acceptor of cholesterol that is exported from cells via ABCA1 and SR-B1, depletion of excess cholesterol is a potential mechanism by which apoA-I may have enhanced insulin secretion in Ins-1E cells. However, we have reported previously, and confirm that this is not the case in the present study, as incubation with apoA-I increased insulin secretion in an ABCA1-and SR-B1-dependent manner without altering cellular cholesterol levels. 10 This led us to ask whether apoA-I increases β-cell insulin secretion by activating cell signaling pathways.
Because the phosphoinositide 3-kinase (PI3K)/Akt signal transduction pathway plays a key role in the response of pancreatic β-cells to mediators of insulin release, 17 and this pathway is also activated when HDL bind to SR-B1 in endothelial cells 24 and mononuclear cells, 25 this was explored in the first instance. However, we found no evidence of activation of the PI3K/Akt by apoA-I in Ins-1E cells. Similarly, incubation of Ins-1E cells with apoA-I did not activate the protein kinase C, janus kinase 2, or AMPK pathways. This highlights the complex nature of these pathways in insulin secretion and their potential inhibition by phosphatases such as protein phosphatase 2A 26, 27 and negative insulin signaling feedback loops. It is also possible that apoA-I does not bind to Ins-1E cells with an affinity that is sufficient to activate these pathways.
Because activation of adenylyl cyclases, the secondary messenger cAMP, and PKA can also release insulin from β-cells 28, 29 and improve β-cell survival by increasing expression of IRS-2 30 and reducing apoptosis, 31 this pathway was also explored. Support for involvement of this pathway in the apoA-I-mediated increase in insulin secretion in Ins-1E cells comes from studies showing that HDL increase intracellular cAMP levels in cholesterol-loaded fibroblasts. 32 The results showing that apoA-I activates ≥1 transmembrane adenylyl cyclases, increases intracellular cAMP levels, and activates PKA in Ins-1E cells are consistent with insulin secretion being increased by activation of this pathway. It is noteworthy that this is the same mechanism by which the incretin, glucagonlike peptide-1, increases β-cell insulin synthesis and secretion. 33 One of the key findings to emerge from the present study is that the interaction of apoA-I with ABCA1 increases insulin secretion by activating a transmembrane adenylyl cyclase via the Gαs subunit of a heterotrimeric G-protein. Sequence analysis shows that ABCA1 shares a striking homology with regions of the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor, which also bind to the Gα s heterotrimeric G-protein subunit 34, 35 ( Figure V in the online-only Data Supplement). This binding site consists of a KLK/R motif in the first intracellular domain of ABCA1 that is N-terminally flanked by several hydrophobic residues. When this is considered in light of the observation that apoA-I also activates the cAMP-PKA signaling pathway, it follows that the immediate (1 hour) glucose-mediated increase in insulin secretion in Ins-1E cells is unlikely to involve K + ATP channel closure, 10,28 FoxO1 localization, or increased insulin synthesis.
Because PKA can also directly phosphorylate FoxO1 in endothelial cells, 36 we asked whether this might explain the previously reported apoA-I-mediated increase in insulin synthesis in MIN6 cells 10 and in Ins-1E cells in the present study. The result in Figure 4 showing that apoA-I excludes FoxO1 from the nucleus of Ins-1E cells is consistent with this notion. It also agrees with the observed activation of transcription factors that upregulate the Ins1 and Ins2 genes 37 and the increase in Pdx1 mRNA levels. The combined effects of these events increase insulin gene transcription. 38 As described previously, 39 this suggests that nuclear FoxO1 functions as an insulin repressor in Ins-1E cells. The ability of apoA-I to increase Pdx1 gene transcription also has the capacity to improve β-cell survival. 40 In conclusion, this study sheds new light on the molecular basis by which apoA-I increases insulin synthesis and secretion in pancreatic β-cells and provides an insight as to why therapies that increase apoA-I and HDL levels improve glycemic control in people with type 2 diabetes mellitus and the metabolic syndrome. The results also identify apoA-I, and possibly apoA-I mimetic peptides, as incretin-like molecules that are potentially attractive agents for treating people with type 2 diabetes mellitus and poor glycaemic control. 
